Please assess the completion status of the following clinical trial:

Trial Title: Systems Biology Guided Therapy for Breast Cancer Positive for Oestrogen Receptor After Aromatase Inhibitor and CDK Inhibition

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histologic diagnosis of breast cancer~* Metastatic or incurable~* Prior treatment with an anastrozole or letrozole and a CDK4/6 inhibitor~* Progression while on or within 6 months of stopping the CDK4/6 inhibitor~* At least one lesion amenable to percutaneous biopsy that is not a purely sclerotic bone lesion~* ECOG 0-2~* Age 18 or greater~* Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines.~Exclusion Criteria:~* Prior treatment within 2 years with fulvestrant, alpelisib, everolimus, or capecitabine~* Comorbid disease other than breast cancer with a life expectancy of less than 2 years~* Cancer other than breast cancer that is expected to need treatment within 2 years~* Platelets \< 100,000/microliter~* INR \> 1.5

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).